ALK-positive metastatic NSCLC
GPTKB entity
Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:caused_by |
cough
chest pain shortness of breath |
| https://www.w3.org/2000/01/rdf-schema#label |
ALK-positive metastatic NSCLC
|
| gptkbp:is_associated_with |
gptkb:fandom
fatigue weight loss poor prognosis clinical symptoms pleural effusion treatment side effects brain metastases |
| gptkbp:is_characterized_by |
tumor heterogeneity
metastasis cellular signaling pathways abnormal cell growth ALK rearrangement |
| gptkbp:is_considered |
gptkb:hospital
radiation therapy |
| gptkbp:is_evaluated_by |
genetic testing
biomarker testing progression-free survival response assessment |
| gptkbp:is_linked_to |
gptkb:municipality
environmental factors patient outcomes EGFR mutations RO S1 rearrangements family history of lung cancer |
| gptkbp:is_monitored_by |
CT scans
PET scans |
| gptkbp:is_often_used_in |
non-smokers
younger patients |
| gptkbp:is_part_of |
gptkb:healthcare_organization
cancer care precision medicine oncology research advanced lung cancer |
| gptkbp:is_studied_in |
clinical trials
molecular profiling drug resistance research |
| gptkbp:is_subject_to |
gptkb:vaccine
targeted therapy |
| gptkbp:modifications |
gptkb:ALK_gene
|
| gptkbp:social_responsibility |
imaging studies
biopsy |
| gptkbp:treatment |
gptkb:brigatinib
gptkb:lorlatinib gptkb:alectinib gptkb:ceritinib gptkb:crizotinib combination therapy maintenance therapy |
| gptkbp:bfsParent |
gptkb:Ceritinib
gptkb:ceritinib |
| gptkbp:bfsLayer |
6
|